Cedrik M. Britten, Chief Medical Officer at Immatics Biotechnologies, shared on LinkedIn:
“Today, I share few impressions from an inspiring ESMO in Madrid! A special thank you to Antonia Busse, Sapna Patel and Dirk Schadendorf for presenting our data on behalf of all co-authors, and to everyone who joined us for the scientific exchange.
Next up is a trip to Phoenix, to the annual meeting of the Society for Immunotherapy of Cancer (SITC). I’m looking forward to continuing the conversations and seeing many of you there!
- On November 5th, I will give two talks: one on the initial clinical results from our TCR-based bispecific T-cell engager programs targeting PRAME and MAGEA4/8, and the other on learnings from our PRAME-directed TCR T-cell therapies in solid tumors.
- On November 6th, CEO Harpreet Singh will present initial clinical results from IMA402, our PRAME-targeting bispecific T-cell engager.
- Two poster presentations by Diwakar Davar and Regina Mendrzyk will feature data on anzu-cel and IMA203CD8.
- The Immatics team will also be at booth 1119 throughout the meeting.
Check out our website for all presentation dates and titles.”
You can also read: 25 Posts Not to Miss from ESMO Congress 2026: Day 5
